Agilent Unifies North American CDMO Capabilities Under New Brand

Agilent Technologies has officially launched Agilent Advanced Therapeutics, a unified Contract Development and Manufacturing Organization (CDMO) service. This initiative integrates the company's existing manufacturing capabilities in Canada and the United States, aiming to provide clients with a streamlined, end-to-end solution.

The new Agilent Advanced Therapeutics platform combines the strengths of BIOVECTRA in Canada with the Nucleic Acid Solutions operations in Colorado. The service portfolio encompasses the manufacturing of oligonucleotides, microbial fermentation, complex synthetic chemistry, bioreagents, and highly potent APIs, alongside cell line development.

This integrated platform is designed to offer customers a single point of contact for services spanning the entire lifecycle, from discovery and process development through clinical and commercial-scale manufacturing. Agilent stated the move reinforces its commitment to growth and leadership in the contract manufacturing sector.

Agilent Technologies reported revenue of $6.95 billion in fiscal year 2025 and employs approximately 18,000 people worldwide. The company provides analytical and clinical laboratory technologies that enable customers to bring their scientific discoveries to fruition.